Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Jul;19(7):731-43.
doi: 10.1089/hum.2008.001.

TRAIL recombinant adenovirus triggers robust apoptosis in multidrug-resistant HL-60/Vinc cells preferentially through death receptor DR5

Ching-Huang Wu  1 , Ching-Hai Kao, Ahmad R Safa
Affiliations

TRAIL recombinant adenovirus triggers robust apoptosis in multidrug-resistant HL-60/Vinc cells preferentially through death receptor DR5

Ching-Huang Wu et al. Hum Gene Ther. 2008 Jul.

Abstract

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising cancer therapeutic because of its highly selective apoptosis-inducing action on neoplastic versus normal cells. However, some cancer cells express resistance to recombinant soluble TRAIL. To overcome this problem, we used a TRAIL adenovirus (Ad5/35-TRAIL) to induce apoptosis in a drug-sensitive and multidrug-resistant variant of HL-60 leukemia cells and determined the molecular mechanisms of Ad5/35-TRAIL-induced apoptosis. Ad5/35-TRAIL did not induce apoptosis in normal human lymphocytes, but caused massive apoptosis in acute myelocytic leukemia cells. It triggered more efficient apoptosis in drug-resistant HL-60/Vinc cells than in HL-60 cells. Treating the cells with anti-DR4 and anti-DR5 neutralizing antibodies (particularly anti-DR5) reduced, whereas anti-DcR1 antibody enhanced, the apoptosis triggered by Ad5/35-TRAIL. Whereas Ad5/35-TRAIL induced apoptosis in both cell lines through activation of caspase-3 and caspase-10, known to link the cell death receptor pathway to the mitochondrial pathway, it triggered increased mitochondrial membrane potential change (m) only in HL-60/Vinc cells. Ad5/35-TRAIL also increased the production of reactive oxygen species, which play an important role in apoptosis. Therefore, using Ad5/35-TRAIL may be an effective therapeutic strategy for eliminating TRAIL-resistant malignant cells and these studies may provide clues to treat and eradicate acute myelocytic leukemias.

PubMed Disclaimer

Figures

FIG. 1.
FIG. 1.
Dose-dependent TRAIL- and Ad5/35-TRAIL-induced apoptosis in the drug-sensitive HL-60 cell line and its P-gp-overexpressing MDR variant, HL-60/Vinc. (A) Western blot analysis of endogenous P-gp levels in HL-60 and HL-60/Vinc cells. Western blotting was performed as described in Materials and Methods. (B) Effect of TRAIL on apoptotic cell death in HL-60 and HL-60/Vinc cells. Cells (5 × 105) were treated for 24 hr with or without TRAIL at 10, 20, 50, and 100 ng/ml, and apoptosis was measured by annexin V-binding assay. Significant differences between 10- and 100-ng/ml TRAIL treatments were obtained (*p < 0.003, **p < 0.001). (C) Effect of Ad5/35-TRAIL on apoptotic cell death in HL-60 and HL-60/Vinc cells. Cells (5 × 105) were treated for 24 hr with or without 5, 10, 20, and 50 MOI of Ad5/35-TRAIL, and apoptosis was measured by annexin V-binding assay. Significant differences between 5 and 50 MOI of Ad5/35-TRAIL treatments were obtained (*p < 0.002, **p < 0.001).
FIG. 2.
FIG. 2.
TRAIL- and Ad5/35-TRAIL-induced apoptosis in the drug-sensitive HL-60 cell line and its P-gp-expressing MDR variant, HL-60/Vinc. (A) Effect of TRAIL and Ad5/35-TRAIL on apoptotic cell death in HL-60 and HL-60/Vinc cells. Cells (5 × 105) were treated with or without 50 MOI of Ad5/35, TRAIL at 20 ng/ml, and 50 MOI of Ad5/35-TRAIL for 24 hr, and apoptosis was measured by annexin V-binding assay. Significant differences between various treatments were obtained (*p < 0.004, **p < 0.0008). (B) Analysis of trimeric, dimeric, and monomeric TRAIL expression in cell lysate. HL-60 and HL-60/Vinc cells (5 × 106) were incubated with or without 50 MOI of Ad5/35, TRAIL at 20 ng/ml, or 50 MOI of Ad5/35-TRAIL at 37°C for 24 hr followed by protein extraction. Aliquots (50 μg of protein per lane) were separated by 5–15% SDS–PAGE and subjected to Western blot analysis as described in Materials and Methods. Equivalent loading was confirmed by reprobing the blot with anti-β-actin. Lanes 1–4 in each panel are HL-60/control, Ad5/35 vector, TRAIL, and Ad5/35-TRAIL, respectively. Lanes 5–8 in each panel are HL-60/Vinc control, Ad5/35 vector, TRAIL, and Ad5/35-TRAIL, respectively.
FIG. 3.
FIG. 3.
Effect of anti-TRAIL receptor antibodies on (A) TRAIL (*p < 0.01, **p < 0.004, ***p < 0.09) and (B) Ad5/35-TRAIL (*p < 0.007, **p < 0.0001, ***p < 0.06)-induced apoptosis. HL-60 and HL-60/Vinc cells were incubated with anti-DR4, -DR5, or -DcR1 neutralizing antibodies for 3 hr at 37°C, and then the cells were treated with or without 50 MOI of Ad5/35 or 50 MOI of Ad5/35-TRAIL at 37°C for 24 hr; apoptosis was measured by annexin V binding assay as described in Materials and Methods.
FIG. 4.
FIG. 4.
RT-PCR, real-time PCR, and Western blot analysis of c-FLIP expression in HL-60 and HL-60/Vinc cells. (A) Expression of c-FLIPL and c-FLIPS before and after treatment. Lanes 1–4 show c-FLIPL mRNA levels in HL-60/control, HL-60/Ad5/35-TRAIL, HL-60/Vinc/control, and HL-60/Vinc/Ad5/35-TRAIL, respectively. Lanes 5–8 show c-FLIPS mRNA levels in HL-60/control, HL-60/Ad5/35-TRAIL, HL-60/Vinc/control, and HL-60/Vinc/Ad5/35-TRAIL, respectively. (B) Expression levels of c-FLIPL and c-FLIPS mRNA with or without treatments were quantified by real-time PCR. Values represent means ± SD of three independent experiments. (C) Western blot shows little c-FLIPL and c-FLIPS before and after treatment in HL-60 and HL-60/Vinc cells. Lanes 1–4 are HL-60/control, (HL-60)/Ad5/35 vector, (HL-60)/TRAIL, and (HL-60)/Ad5/35-TRAIL, respectively. Lanes 5–8 are HL-60/Vinc/control, (HL-60/Vinc)/Ad5/35 vector, (HL-60/Vinc)/TRAIL, and (HL-60/Vinc)/Ad5/35-TRAIL, respectively.
FIG. 5.
FIG. 5.
TRAIL and Ad5/35-TRAIL trigger caspase activation in HL-60 and HL-60/Vinc cells: (A) caspase-8, (B) caspase-10, (C) caspase-9, and (D) caspase-3. Aliquots (50 μg of protein per lane) were separated by 10% SDS–PAGE and subjected to Western blot analysis as described in Materials and Methods. Lanes 1–4 in each panel are HL-60/control, HL-60/Ad5/35 vector, HL-60/TRAIL, and HL-60/Ad5/35-TRAIL, respectively. Lanes 5–8 in each panel are HL-60/Vinc/control, HL-60/Vinc/Ad5/35 vector, HL-60/Vinc/TRAIL, and HL-60/Vinc/Ad5/35-TRAIL, respectively.
FIG. 6.
FIG. 6.
Effect of (A) caspase-3 and (B) caspase-10 inhibitors on TRAIL- and Ad5/35-TRAIL-induced apoptosis. HL-60 and HL-60/Vinc cells were incubated in growth medium in the presence or absence of 50 μM caspase-3 inhibitor Ac-DEVD-CHO for 3 hr at 37°C, and then the cells were treated with or without 50 MOI of Ad5/35, TRAIL at 20 ng/ml, or 50 MOI of Ad5/35-TRAIL at 37°C for 24 hr, and apoptosis was measured by annexin V binding assay as described in Materials and Methods. (A) *p < 0.005, **p < 0.02, ***p < 0.03; (B) *p < 0.008, **p < 0.001.
FIG. 7.
FIG. 7.
Effect of Ad5/35-TRAIL on mitochondrial potential change (Δψm). Cells (5 × 105) were treated with or without 50 MOI of Ad5/35, TRAIL at 20 ng/ml, or 50 MOI of Ad5/35-TRAIL at 37°C for 24 hr, and 5,5′,6,6′-tetrachloro-1,1′,3,3′-tetraethylbenzimidazolyl carbocyanine (JC-1) was used as a probe as described in Materials and Methods. JC-1 membrane potential-related fluorescence was recorded with an FL1 photomultiplier tube (PMT) and a FACSCalibur flow cytometer. This experiment was performed in triplicate and results are shown as means ± SD.
FIG. 8.
FIG. 8.
Analysis of reactive oxygen species (ROS) in TRAIL- and Ad5/35-TRAIL-triggered apoptosis. Cells (5 × 105) were treated with or without 50 MOI of Ad5/35, TRAIL at 20 ng/ml, or 50 MOI of Ad5/35-TRAIL at 37°C for 24 hr. After treatment, the cells were incubated for 30 min at 37°C with 5 μM dichlorodihydrofluorescein diacetate (DCFH-DA) and analyzed with a FACSCalibur flow cytometer as described by the manufacturer (*p < 0.005, **p < 0.0008).
FIG. 9.
FIG. 9.
NAc effect on TRAIL- and Ad5/35-TRAIL-induced apoptosis: (A) HL-60 cells; (B) HL-60/Vinc cells. Cells (5 × 105) were incubated with 10 mM NAc for 3 hr before being treated with or without 50 MOI of Ad5/35, TRAIL at 20 ng/ml, or 50 MOI of Ad5/35-TRAIL at 37°C for 24 hr; apoptosis was determined by annexin V flow cytometry as described in text. NAc decreases Ad5/35-TRAIL-induced apoptosis: (A) *p < 0.004, **p < 0.005; (B) *p < 0.005, **p < 0.001.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Abedini M.R. Qiu Q. Yan X. Tsang B.K. Possible role of FLICE-like inhibitory protein (FLIP) in chemoresistant ovarian cancer cells in vitro. Oncogene. 2004;23:6997–7004. - PubMed
    1. Ashkenazi A. Pai R.C. Fong S. Leung S. Lawrence D.A. Marsters S.A. Blackie C. Chang L. McMurtrey A.E. Hebert A. Deforge L. Koumenis I.L. Lewis D. Harris L. Bussiere J. Koeppen H. Shahrokh Z. Schwall R.H. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest. 1999;104:155–162. - PMC - PubMed
    1. Balamotis M.A. Huang K. Mitani K. Efficient delivery and stable gene expression in a hematopoietic cell line using a chimeric serotype 35 fiber pseudotyped helper-dependent adenoviral vector. Virology. 2004;324:229–237. - PubMed
    1. Bedi A. Zehnbauer B.A. Barber J.P. Sharkis S.J. Jones R.J. Inhibition of apoptosis by BCR-ABL in chronic myeloid leukemia. Blood. 1994;83:2038–2044. - PubMed
    1. Bedi A. Barber J.P. Bedi G.C. El-Deiry W.S. Sidransky D. Vala M.S. Akhtar A.J. Hilton J. Jones R.J. BCR-ABL mediated inhibition of apoptosis with delay of G2/M transition after DNA damage: A mechanism of resistance to multiple anticancer agents. Blood. 1995;86:1148–1158. - PubMed

Publication types

MeSH terms

Substances